Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-06-28
2011-06-28
Ward, Paul V. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S336000
Reexamination Certificate
active
07968547
ABSTRACT:
Disclosed are compounds which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.
REFERENCES:
patent: 4018913 (1977-04-01), Okamoto et al.
patent: 4018915 (1977-04-01), Okamoto et al.
patent: 4036955 (1977-07-01), Okamoto et al.
patent: 4041156 (1977-08-01), Okamoto et al.
patent: 4046876 (1977-09-01), Okamoto et al.
patent: 4055636 (1977-10-01), Okamoto et al.
patent: 4055651 (1977-10-01), Okamoto et al.
patent: 4070457 (1978-01-01), Okamoto et al.
patent: 4073914 (1978-02-01), Kikumoto et al.
patent: 4085057 (1978-04-01), Masuda et al.
patent: 4096255 (1978-06-01), Kikumoto et al.
patent: 4104392 (1978-08-01), Okamoto et al.
patent: 4235871 (1980-11-01), Paphadjopoulos et al.
patent: 4438122 (1984-03-01), Holmwood et al.
patent: 4501728 (1985-02-01), Geho et al.
patent: 4505910 (1985-03-01), Bagli
patent: 4518600 (1985-05-01), Holmwood et al.
patent: 4544402 (1985-10-01), Schnurbusch et al.
patent: 4559345 (1985-12-01), Gomarasca et al.
patent: 4672065 (1987-06-01), Spatz
patent: 4837028 (1989-06-01), Allen et al.
patent: 4908368 (1990-03-01), Murase et al.
patent: 4959364 (1990-09-01), Mueller et al.
patent: 4992439 (1991-02-01), Meanwell
patent: 5011472 (1991-04-01), Aebischer et al.
patent: 5023252 (1991-06-01), Hseih et al.
patent: 5030644 (1991-07-01), Baldwin et al.
patent: 5120734 (1992-06-01), Klausener et al.
patent: 5238934 (1993-08-01), Knuppel et al.
patent: 5278184 (1994-01-01), Artico et al.
patent: 5510332 (1996-04-01), Kogan et al.
patent: 5580868 (1996-12-01), Lunkenheimer et al.
patent: 5770573 (1998-06-01), Arrhenius et al.
patent: 5814643 (1998-09-01), Duggan et al.
patent: 5861429 (1999-01-01), Sato et al.
patent: 5925644 (1999-07-01), Jakobi et al.
patent: 5942504 (1999-08-01), Grobelny
patent: 5955491 (1999-09-01), Sohda et al.
patent: 5962479 (1999-10-01), Chen
patent: 5972946 (1999-10-01), Murata et al.
patent: 6005117 (1999-12-01), Wehner et al.
patent: 6436904 (2002-08-01), Ashwell et al.
patent: 6479492 (2002-11-01), Konradi et al.
patent: 6492372 (2002-12-01), Konradi et al.
patent: 6544994 (2003-04-01), Rabelink et al.
patent: 6545003 (2003-04-01), Grant et al.
patent: 6689781 (2004-02-01), Konradi et al.
patent: 6794506 (2004-09-01), Konradi et al.
patent: 6903088 (2005-06-01), Konradi et al.
patent: 6911439 (2005-06-01), Konradi et al.
patent: 7005433 (2006-02-01), Konradi et al.
patent: 7008949 (2006-03-01), Konradi et al.
patent: 7026328 (2006-04-01), Konradi et al.
patent: 7049306 (2006-05-01), Konradi et al.
patent: 7135477 (2006-11-01), Konradi et al.
patent: 7335663 (2008-02-01), Konradi et al.
patent: 7378529 (2008-05-01), Konradi et al.
patent: 7427628 (2008-09-01), Konradi et al.
patent: 7452912 (2008-11-01), Grant et al.
patent: 2005/0203093 (2005-09-01), Konradi et al.
patent: 2005/0261293 (2005-11-01), Konradi et al.
patent: 2006/0013799 (2006-01-01), Konradi et al.
patent: 2007/0099921 (2007-05-01), Konradi et al.
patent: 2007/0129390 (2007-06-01), Semko et al.
patent: 2007/0142416 (2007-06-01), Semko et al.
patent: 2008/0058357 (2008-03-01), Smith et al.
patent: 2241149 (1997-07-01), None
patent: 2259224 (1998-01-01), None
patent: 2359115 (2000-07-01), None
patent: 195 36 891 (1997-04-01), None
patent: 265 56 36 (1997-06-01), None
patent: 195 48 709 (1997-07-01), None
patent: 196 54 483 (1998-01-01), None
patent: 197 13 000 (1998-10-01), None
patent: 116494 (1984-08-01), None
patent: 0 147 211 (1985-07-01), None
patent: 0 288 176 (1988-10-01), None
patent: 0 330 506 (1989-08-01), None
patent: 0 526 348 (1993-02-01), None
patent: 0 535 521 (1993-04-01), None
patent: 1500063 (1978-02-01), None
patent: 169926 (1977-02-01), None
patent: 59212480 (1984-12-01), None
patent: WO 91/05038 (1991-04-01), None
patent: WO 92/16549 (1992-10-01), None
patent: WO 93/12809 (1993-07-01), None
patent: WO 93/24154 (1993-12-01), None
patent: WO 96/01644 (1996-01-01), None
patent: WO 96/22966 (1996-08-01), None
patent: WO 96/32383 (1996-10-01), None
patent: WO 97/23451 (1997-07-01), None
patent: WO 97/48726 (1997-12-01), None
patent: WO 98/00395 (1998-01-01), None
patent: WO 98/22430 (1998-05-01), None
patent: WO 98/33783 (1998-08-01), None
patent: WO 98/53814 (1998-12-01), None
patent: WO 98/53817 (1998-12-01), None
patent: WO 99/06390 (1999-02-01), None
patent: WO 99/06391 (1999-02-01), None
patent: WO 99/06431 (1999-02-01), None
patent: WO 99/06432 (1999-02-01), None
patent: WO 99/06433 (1999-02-01), None
patent: WO 99/10312 (1999-03-01), None
patent: WO 99/10313 (1999-03-01), None
patent: WO 99/37605 (1999-07-01), None
patent: WO 99/37618 (1999-07-01), None
patent: WO 99/52898 (1999-10-01), None
patent: WO 00/18759 (2000-04-01), None
patent: WO 00/31067 (2000-06-01), None
patent: WO 00/43369 (2000-07-01), None
patent: WO 00/43371 (2000-07-01), None
patent: WO 00/43372 (2000-07-01), None
patent: WO 02/08201 (2002-01-01), None
patent: WO 03/099231 (2003-12-01), None
patent: WO 03/099809 (2003-12-01), None
patent: WO 2005/111020 (2005-11-01), None
patent: WO 2007/041270 (2007-04-01), None
patent: WO 2007/041324 (2007-04-01), None
patent: WO 2007/101165 (2007-09-01), None
Wolff, M.E., “Burger's Medicinal Chemistry”, 5th Ed., Part 1, pp. 975-977 (1995).
Banker et al., “Modern Pharmaceuticals”, 3rd Ed., p. 596 (1996).
U.S. Appl. No. 12/645,154, filed Dec. 22, 2009, Konradi et al.
U.S. Appl. No. 12/579,828, filed Oct. 15, 2009, Semko et al.
Abraham, W.M., et al. “α4-Integrins Mediate Antigen-induced Late Bronchial Responses and Prolonged Airway Hyperresponsiveness in Sheep.”J. Clin. Invest. 93: 776-787 (1994).
Abraham, et al., “Blockade of Late-phase Airway Responses and Airway Hyperresponsiveness in allergic Sheep with a Small-molecule Peptide Inhibitor of VLA-4,”Am J Resper Crit Care Med156:696-703 (1997).
Advani, S.B., et al. “Potential Antineoplastic Agents: N-(2-Benzoxazolyl)amino Acid Esters.”J. of Pharm. Sci. 57(10): 1693-1696 (1968).
Anderson, et al., “Acute kidney graft rejection,”APMIS102, 23-37 (1994).
Anderson, et al., “Process Development of 5-Fluoro-3-[3-[4-(5-methoxy-4 pyrimidinyl)-1 piperazinyl]propyl]-1H-indole Dihydrochloride,”Org Proc Res Devel1:300-310 (1997).
Balaban, I., “An Investigation into the Formation of 4(5)-Aminoglyoxalines,”J. chem.. soc. Part 1:1-268-273 (1930).
Bao, L., et al. “Correlation of VLA-4 integrin expression with metastatic potential in various human tumour cell lines.”Diff. 52: 239-246 (1993).
Banker, G.S. et al., “Modern Pharmaceutics, 3ed.”, Marcel Dekker, New York, pp. 451-596 (1996).
Baron, J.L., et al. “Surface Expression of α4 Integrin by CD4 T Cells is Required for Their Entry into Brain Parenchyma.”J. Exp. Med. 177: 57-68 (1993).
Baron, J.L., et al. “The Pathogenesis of Adeoptive Murine Autonimmune Diabetes Requires an Interaction between α4-Integrins and Vascular Cell Adhesion Molecule-1.”J. Clin. Invest. 93: 1700-1708 (1994).
Belka et al., “Radiation induced CNS toxicity—Molecular and cellular mechanism”Br. J. Cancer85:1233-1239 (2001).
Burkly, L.C., et al. “Protection Against Adoptive Transfer of Autoimmune Diabetes Mediated Through Very Late Antigent-4 Integrin.”Diabetes. 43: 529-534 (1994).
Casanova et al., PubMed Abstract (Rev Neurol.) 28(9):909-915 (1999).
Chapman et al. “Time course of allergen-induced leukocyte accumulation in actively sensitized brown Norway rats” Am. J. Resp. Crit. Care Med. 153-154, A219 (1996).
Chapman et al. “Allergen-induced airway hyperreactivity an
Ashwell Susan
Dressen Darren B.
Grant Francine S.
Konradi Andrei W.
Kreft Anthony
Elan Pharmaceuticals Inc.
Foley & Lardner LLP
Ward Paul V.
Wyeth
LandOfFree
Heteroaryl, heterocyclic and aryl compounds which inhibit... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Heteroaryl, heterocyclic and aryl compounds which inhibit..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heteroaryl, heterocyclic and aryl compounds which inhibit... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2729997